查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495986

一次性反應器市場：2024-2029 年預測

Single-Use Bioreactors Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 114 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年一次性反應器市值為38.58億美元，複合年成長率為15.82%，到2029年市場規模將達到107.86億美元。

一次性反應器或一次性反應器是具有一包消耗品而不是培養容器的反應器。通常，這是指與細胞培養物接觸的固定物是塑膠的反應器，這種塗層的需求量很大，而且更環保，因為它被封裝在更持久的結構中。隨著多藥物製劑室不斷擴大，需要使用類似的製劑室來開發多種藥物，並且能夠在不影響藥物品質的情況下適應多種藥物的開發，一次性反應器的需求。一次性反應器市場成長潛力的來源是生物製藥領域不斷增加的研究活動和發展。

一次性反應器在不影響品質的情況下生產多種藥物所提供的靈活性正在增加其在醫療和生物製藥領域的市場價值。此外，一次性反應器降低的自動化複雜性預計將增加大公司和產業對一次性反應器的需求。

支持製藥和生物技術領域研發的政府政策也對全球一次性反應器市場的成長產生正面影響。一次性反應器在減少昂貴且耗時的清洗過程方面所提供的效率預計將在預測期內增強其需求。

市場促進因素：

  • 生物製藥研究和開發的增加預計將推動一次性反應器市場的發展。

由於老年人口比例不斷增加，全世界對生物製藥的興趣日益濃厚。隨著商業機會的擴大，世界各地的組織和領先公司正在增加對生物製藥研發項目的投資。與其他創投公司相比，生物製藥產業在研發方面的貢獻高出許多倍。根據2018年FIP（國際藥學會聯合會）報告，全球生物製藥公司在研發項目上的投資總合約為1,020億美元。

一次性反應器對於生物製藥成分生產過程至關重要。它們在中小型生物製藥生產中佔很大一部分，特別是在臨床試驗和創新工作中。由於其相對於傳統生物製造策略的優勢，它在生物製藥研究和開發中越來越受歡迎。增加研究和開發項目被認為是一次性反應器市場成長的正面訊號。

  • 一次性反應器提供的靈活性可能會顯著增加對一次性反應器的需求。

一次性反應器提供的靈活性也是積極推動一次性反應器市場成長的關鍵因素。由於一次性反應器在各個領域的應用正在擴大。與傳統生物反應器相比，領先公司在一次性反應器開發方面的大量投資顯著促進了全球一次性反應器市場的成長。

一次性反應器由於其對不同規模的適應性、縮短的周轉時間、成本效益以及最小化交叉污染風險而變得越來越受歡迎。它適用於從實驗室規模研究到大規模工業生產的廣泛應用。與傳統的不銹鋼反應器相比，設置和清洗步驟更快，從而實現更有效率的生產週期。

此外，一次性反應器不需要大量的基礎設施或清洗檢驗成本，使其成為經濟的選擇。這對於生物製藥和其他敏感產品的生產尤其重要，因為在這些產品中保持產品純度非常重要。

預計北美地區未來將佔據很大的市場佔有率。

北美是市場領導。從地理位置來看，北美地區估計佔據一次性反應器市場的大部分。北美國家發達的醫療和製藥基礎設施以及領先企業的存在是該地區在一次性反應器市場佔有較大佔有率的主要原因。

北美，特別是美國，是生物製藥行業的世界領導者，有許多生物技術和製藥公司在生產中使用反應器。由於污染風險降低、週轉時間縮短和資本支出降低等優點，對具有靈活性和成本效率的一次性反應器的需求正在上升。該地區生物技術新興企業的成長也推動了一次性反應器的採用，使其成為生物程序開發和製造的有吸引力的選擇。

生物製藥行業主要企業與一次性反應器製造商之間的策略聯盟正在促進市場成長。北美監管機構已經認知到一次性反應器的好處，並支持其在生物製藥生產中的使用。一次性反應器技術的技術進步，例如感測器整合、控制系統和一次性材料，是其更廣泛接受的因素。北美地區在全球生物製藥市場的強勢地位有助於其在一次性反應器市場的競爭力。

主要進展

  • 2022 年 11 月 - 全球生命科學領域的領導者 Cytiva 投資 800 萬美元擴建其位於上海的 Fast Trak 中心，為亞洲快速成長的生物製藥產業提供服務。佔地 11,000平方公尺的工廠提供全面的培訓、製程設計、製造服務、客戶經驗、SUT 創新和驗證服務。升級後的中心規模將是目前的四倍，將成為Cytiva在亞太地區最大的生物技術訓練中心。該中心還將擴大 Cytiva 的生物分子研發和 GMP 中試製造平台，提供遠端和智慧客戶服務，建立 Cytiva 在亞洲的第一個 SUT 卓越中心，並提供持續的製造示範服務。
  • 2022 年 8 月 - Thermo Fisher Scientific 在大納許維爾開設了最大的一次性技術製造工廠，耗資 1.05 億美元。這座佔地 40 萬平方英尺的工廠將為生物製藥公司生產可客製化的生物製程容器和流體傳輸組裝系統。黎巴嫩工廠是賽默飛世爾 6.5 億美元多年投資的一部分，該投資將在工程、採購、品質、倉儲和現場領導等領域創造 1,400 個新就業機會。該設施是 Thermo Fisher 遍布 100 個國家的全球生物程序供應網路的一部分，以確保關鍵藥物到達患者手中。黎巴嫩工廠目前擁有約 300 名員工，是 Thermo Fisher 全球生物製程供應網路的一部分。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章一次性反應器市場：依產品類型

  • 介紹
  • 一次性反應器系統
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 媒體袋
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 過濾組件
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他產品
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章一次性反應器市場：依細胞類型

  • 介紹
  • 哺乳動物細胞
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 細菌
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 酵母菌
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他細胞類型
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章一次性反應器市場：依分子類型

  • 介紹
  • 單株抗體
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 疫苗
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 幹細胞
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 基因改造細胞
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他分子類型
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章一次性反應器市場：依最終用戶分類

  • 介紹
  • 醫藥及生物製藥產業
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • CRO
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他最終用戶
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第9章一次性反應器市場：按地區

  • 介紹
  • 北美洲
    • 依產品類型
    • 按細胞類型
    • 依分子類型
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 依產品類型
    • 按細胞類型
    • 依分子類型
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 依產品類型
    • 按細胞類型
    • 依分子類型
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 依產品類型
    • 按細胞類型
    • 依分子類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 依產品類型
    • 按細胞類型
    • 依分子類型
    • 按最終用戶
    • 按國家/地區

第10章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第11章 公司簡介

  • ABEC Inc.
  • Celltainer
  • Distek Inc.
  • Eppendorf AG
  • GE Healthcare
  • Thermo Fisher Scientific
  • Parker Hannifin
  • Danaher
  • PBS Biotech
  • Cellexus
  • Applikon Biotechnology
簡介目錄
Product Code: KSI061611955

The single-use bioreactors market was evaluated at US$3.858 billion in 2022, growing at a CAGR of 15.82% to reach a market size of US$10.786 billion by 2029.

A solitary-use bioreactor or single-use bioreactor is a bioreactor with an expendable pack rather than a culture vessel. Regularly, this alludes to a bioreactor in which the fixing in touch with the cell culture will be plastic, and this coating is encased inside a more long-lasting construction, so it is high in demand and more eco-friendly. The expanding pattern toward multi-drug offices demands the creation of various drugs utilizing a similar office, which further raises the demand for single-use bioreactors because of their adaptability in the development of different drugs without compromising the quality of drugs. Increasing research activities and developments in the field of biopharmaceutics are giving potential to the market growth of single-use bioreactors.

The flexibility showcased by single-use bioreactors in producing multiple drugs without compromising quality is driving their market value in the medical and biopharmaceutical fields. The reduction in automation complexity offered by single-use bioreactors is also expected to increase the demand for them among large companies and industries.

The policies offered by the governments of several countries in support of research and development in the pharmaceutical and biotechnological fields are also positively influencing the global single-use bioreactors market growth. The efficiency offered by single-use bioreactors by reducing the costly and time-consuming cleaning process is expected to bolster their demand during the forecast period.

Market Drivers:

  • Rise in biopharmaceutical research and development is expected to drive the single-use bioreactors market

The interest in biopharmaceuticals is expanding worldwide because of the growing geriatric population percentage, as this population is more susceptible to a wide scope of infections. Looking at the increasing opportunities, worldwide organizations, and major companies are investing more in biopharmaceutical research and development programs. When compared to other assembling ventures, the biopharmaceutical industry contributes many times more in terms of research and development. According to the reports of the FIP (International Pharmaceutical Federation) in 2018, the world's biopharmaceutical organizations had collectively invested about 102 billion USD in research and development programs.

Single-use bioreactors are vital to the biopharmaceutical component-producing work processes. They make up an enormous amount of small and mid-scale biopharmaceutical manufacturing, especially in clinical testing and innovative work. Because of their benefits over traditional biomanufacturing strategies, their popularity has expanded in biopharmaceutical research and development. The increasing research and development programs are considered a positive sign for the single-use bioreactor market's growth.

  • The flexibility offered by single-use bioreactors would significantly increase the demand for single-use bioreactors.

The flexibility offered by single-use bioreactors is another major factor positively driving the single-use bioreactor market's growth. The efficiency showcased by these bioreactors in manufacturing different types of drugs and assisting different biopharmaceutical processes is increasing the application of single-use bioreactors in various fields. The large investments of major companies in developing single-use bioreactors compared to conventional ones are significantly boosting the global single-use bioreactor market growth.

Single-use bioreactors are increasingly popular due to their adaptability to various scales, reduced turnaround time, cost-effectiveness, and minimization of cross-contamination risks. They are suitable for a wide range of applications, from laboratory-scale research to large-scale industrial production. The setup and cleaning processes are faster than traditional stainless-steel bioreactors, allowing for more efficient production cycles.

Additionally, single-use bioreactors eliminate the need for significant infrastructure and cleaning validation costs, making them an economical choice. This is particularly important in the production of biopharmaceuticals and other sensitive products, where maintaining product purity is crucial.

The North American region is predicted to hold a significant market share in the future.

North America is the market leader. Geographically, the North American region is estimated to hold the lion's share of the single-use bioreactor market. The presence of well-established medical and pharmaceutical infrastructure in the North American countries and the presence of major players are some of the prominent reasons behind the region's large market share in the single-use bioreactor market.

North America, particularly the United States, is a global leader in the biopharmaceutical industry, with numerous biotech and pharmaceutical companies using bioreactors for production. The demand for single-use bioreactors, offering flexibility and cost-efficiency, is on the rise due to their advantages such as reduced contamination risk, faster turnaround times, and lower capital investment. The growth of biotechnology startups in the region has also driven the adoption of single-use bioreactors, making them an attractive choice for bioprocess development and manufacturing.

Strategic collaborations between key players in the biopharmaceutical industry and single-use bioreactor manufacturers contribute to market growth. Regulatory agencies in North America have recognized the advantages of single-use bioreactors and provided support for their use in biopharmaceutical manufacturing. Technological advancements in single-use bioreactor technology, such as sensor integration, control systems, and disposable materials, contribute to their broader acceptance. The North American region's strong presence in the global biopharmaceutical market contributes to its competitiveness in the single-use bioreactors marketplace.

Key Developments:

  • November 2022- Cytiva, a global life sciences leader, is investing USD 8 million to expand its Fast Trak center in Shanghai to serve Asia's rapidly-growing biopharma industry. The 11,000 m2 facility will offer comprehensive training, process design, manufacturing services, customer experience, SUT innovation, and validation services. The upgraded center will be four times larger than its current size and will host Cytiva's largest biotech training center in the Asia Pacific region. It will also expand Cytiva's biomolecule R&D and GMP pilot manufacturing platform, provide remote and intelligent customer services, house Cytiva's first SUT center of excellence in Asia, and offer continuous manufacturing demonstration services.
  • August 2022- Thermo Fisher Scientific has opened its largest single-use technology manufacturing site in Greater Nashville, a $105 million facility. The 400,000-square-foot facility will manufacture customizable BioProcess Containers and fluid transfer assembly systems for biopharma companies. The Lebanon facility, part of Thermo Fisher's $650 million multi-year investment, will create 1,400 new jobs across engineering, procurement, quality, warehousing, and site leadership. The site is part of Thermo Fisher's global bioprocessing supply network, which expands across 100 countries to ensure critical medicines reach patients. The Lebanon site currently employs around 300 people and is part of Thermo Fisher's global bioprocessing supply network.

Key Market Segmentation:

By Product Type

  • Single-Use Bioreactor Systems
  • Media Bags
  • Filtration Assemblies
  • Other Products

By Cell Type

  • Mammalian cell
  • Bacteria
  • Yeast
  • Other Cell Types

By Molecule Type

  • Monoclonal Antibodies
  • Vaccines
  • Stem Cells
  • Gene-modified Cells
  • Other Molecule Types

By End-User

  • Pharmaceutical and Biopharmaceutical industries
  • Contract Research Organisations
  • Other End-Users

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. SINGLE-USE BIOREACTORS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Single-Use Bioreactor Systems
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Media Bags
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Filtration Assemblies
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Other Products
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. SINGLE-USE BIOREACTORS MARKET BY CELL TYPE

  • 6.1. Introduction
  • 6.2. Mammalian cell
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Bacteria
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Yeast
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Other Cell Types
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. SINGLE-USE BIOREACTORS MARKET BY MOLECULE TYPE

  • 7.1. Introduction
  • 7.2. Monoclonal Antibodies
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Vaccines
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Stem Cells
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Gene-modified Cells
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness
  • 7.6. Other Molecule Types
    • 7.6.1. Market Opportunities and Trends
    • 7.6.2. Growth Prospects
    • 7.6.3. Geographic Lucrativeness

8. SINGLE-USE BIOREACTORS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Pharmaceutical and Biopharmaceutical industries
    • 8.2.1. Market Opportunities and Trends
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness
  • 8.3. Contract Research Organisations
    • 8.3.1. Market Opportunities and Trends
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness
  • 8.4. Other End-Users
    • 8.4.1. Market Opportunities and Trends
    • 8.4.2. Growth Prospects
    • 8.4.3. Geographic Lucrativeness

9. SINGLE-USE BIOREACTORS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Product Type
    • 9.2.2. By Cell Type
    • 9.2.3. By Molecule Type
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
        • 9.2.5.1.1. Market Opportunities and Trends
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Opportunities and Trends
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Opportunities and Trends
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Product Type
    • 9.3.2. By Cell Type
    • 9.3.3. By Molecule Type
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Opportunities and Trends
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Opportunities and Trends
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Opportunities and Trends
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Product Type
    • 9.4.2. By Cell Type
    • 9.4.3. By Molecule Type
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. Germany
        • 9.4.5.1.1. Market Opportunities and Trends
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. France
        • 9.4.5.2.1. Market Opportunities and Trends
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. UK
        • 9.4.5.3.1. Market Opportunities and Trends
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Others
        • 9.4.5.4.1. Market Opportunities and Trends
        • 9.4.5.4.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Product Type
    • 9.5.2. By Cell Type
    • 9.5.3. By Molecule Type
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Opportunities and Trends
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. UAE
        • 9.5.5.2.1. Market Opportunities and Trends
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Others
        • 9.5.5.3.1. Market Opportunities and Trends
        • 9.5.5.3.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Product Type
    • 9.6.2. By Cell Type
    • 9.6.3. By Molecule Type
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
        • 9.6.5.1.1. Market Opportunities and Trends
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. India
        • 9.6.5.2.1. Market Opportunities and Trends
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. Japan
        • 9.6.5.3.1. Market Opportunities and Trends
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Opportunities and Trends
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Taiwan
        • 9.6.5.5.1. Market Opportunities and Trends
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Thailand
        • 9.6.5.6.1. Market Opportunities and Trends
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Indonesia
        • 9.6.5.7.1. Market Opportunities and Trends
        • 9.6.5.7.2. Growth Prospects
      • 9.6.5.8. Others
        • 9.6.5.8.1. Market Opportunities and Trends
        • 9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. ABEC Inc.
  • 11.2. Celltainer
  • 11.3. Distek Inc.
  • 11.4. Eppendorf AG
  • 11.5. GE Healthcare
  • 11.6. Thermo Fisher Scientific
  • 11.7. Parker Hannifin
  • 11.8. Danaher
  • 11.9. PBS Biotech
  • 11.10. Cellexus
  • 11.11. Applikon Biotechnology